

Active substances set

Search phrase: belzutifan

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Kidney cancer

Belzutifan	Renal cell carcinoma (RCC) Belzutifan is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.	REIMBURSEMENT WITH RESTRICTIONS ESMO